ARVN
Arvinas, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website arvinas.com
- Employees(FY) 415
- ISIN US04335A1051
Performance
+2.28%
1W
-2.27%
1M
-37.53%
3M
+57.12%
6M
-20.6%
YTD
+40.86%
1Y
Profile
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Investment Analysis Report: ARVN
Overview
In this investment analysis report, we will delve into the financial statements of ARVN, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the Balance Sheets, Income Statements, and Cashflow Statements to gain insights into the company's financial heal...
Technical Analysis of ARVN 2024-05-10
Overview:
In analyzing the technical indicators for ARVN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-16 09:10
- 2024-05-16 07:01
- 2024-05-16 06:00
- 2024-05-15 20:07
- 2024-05-15 18:00
- 2024-05-11 08:03
- 2024-05-09 16:42
- 2024-05-09 04:42
- 2024-05-08 06:57
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth(Simply Wall St.)
- 2024-05-07 20:36
- 2024-05-07 10:27
Arvinas Shares Up After Q1 Net Loss Narrows(MT Newswires)
- 2024-05-07 08:15
- 2024-05-07 07:00
- 2024-05-07 01:54
- 2024-05-06 20:15
- 2024-05-06 19:00
- 2024-05-02 10:00
- 2024-05-02 07:00
Arvinas to Present at Upcoming Investor Conferences(GlobeNewswire)
- 2024-05-01 22:00
- 2024-05-01 19:00
Arvinas to Present at Upcoming Investor Conferences(Globenewswire)
- 2024-05-01 12:00
- 2024-05-01 00:00
- 2024-04-30 10:01
- 2024-04-29 22:30
- 2024-04-26 10:00
- 2024-04-25 22:00
- 2024-04-24 16:30
- 2024-04-24 04:30
- 2024-04-12 13:55
- 2024-04-11 12:25
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024(Associated Press Finance)
Page 1 of 6
previousnext